847555-93-5

Usage

Uses

Used in Pharmaceutical Industry:
1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one is used as a compound with potential pharmaceutical applications due to its distinctive structural features. Its heterocyclic nature, which includes nitrogen and oxygen in the ring, is being studied for possible biological activities that could lead to the development of new drugs or therapeutic agents.
It is crucial to handle 1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one with care and adhere to safety guidelines when working with it in a laboratory setting to ensure the safety of researchers and the integrity of the experiments.

Upstream product

• 847553-76-8 3-oxo-1,1-diphenyltetrahydrooxazolo[3,4-a]pyrazine-7-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 591-51-5 phenyllithium 
• 24424-99-5 di-tert-butyl dicarbonate 
• 17532-20-6 diphenyl(piperazin-2-yl)methanol 
• 17532-22-8 (1,4-dibenzyl-piperazin-2-yl)-diphenyl-methanol 
• 847555-98-0 7-benzyl-1,1-diphenyl-hexahydro-1H-[1,3]oxazolo[3,4-a]-piperazin-3-one 

Downstream Products

• 1056637-49-0 C₂₅H₃₀N₄O₃S 
• 1056637-50-3 C₂₆H₃₂N₄O₂S 
• 1056637-36-5 C₂₇H₂₆FN₃O₃ 

Relevant academic research and scientific papers

Structure-Activity Relationship Studies on Oxazolo[3,4- a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent in Vivo Activity

Neuropeptide S modulates important neurobiological functions including locomotion, anxiety, and drug abuse through interaction with its G protein-coupled receptor known as neuropeptide S receptor (NPSR). NPSR antagonists are potentially useful for the treatment of substance abuse disorders against which there is an urgent need for new effective therapeutic approaches. Potent NPSR antagonists in vitro have been discovered which, however, require further optimization of their in vivo pharmacological profile. This work describes a new series of NPSR antagonists of the oxazolo[3,4-a]pyrazine class. The guanidine derivative 16 exhibited nanomolar activity in vitro and 5-fold improved potency in vivo compared to SHA-68, a reference pharmacological tool in this field. Compound 16 can be considered a new tool for research studies on the translational potential of the NPSergic system. An in-depth molecular modeling investigation was also performed to gain new insights into the observed structure-activity relationships and provide an updated model of ligand/NPSR interactions.

Identification of neuropeptide s antagonists: Structure-Activity relationship studies, x-ray crystallography, and in vivo evaluation

Modulation of the neuropeptide S (NPS) system has been linked to a variety of CNS disorders such as panic disorder, anxiety, sleeping disorders, asthma, obesity, PTSD, and substance abuse. In this study, a series of diphenyltetrahydro-1H-oxazolo[3,4-α]pyr

Identifying structural features on 1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-ones critical for Neuropeptide S antagonist activity

A series of 7-substituted 1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-ones were synthesized and tested for Neuropeptide S (NPS) antagonist activity. A concise synthetic route was developed, which features a DMAP catalyzed carbamate formation. 4-Fluorob

BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF

The present invention provides a compound represented by the formula: wherein R1 is an acyl group, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, a sulfur atom or the like, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.